What evidence has the @JHSPH_NCRC reviewed to date on treatments for COVID-19? 💊💉🩸
From Gautret et al. in International Journal of Antimicrobial Agents:
Viral shedding appeared lower in the #hydroxychloroquine arm; however, important differences between groups may also explain the effect seen. bit.ly/2W5meov
Viral shedding appeared lower in the #hydroxychloroquine arm; however, important differences between groups may also explain the effect seen. bit.ly/2W5meov
From Gautret et al. in International Journal of Antimicrobial Agents:
The study did not formally assess clinical endpoints, and it is unclear whether there is #COVID19 clinical benefit with #hydroxychloroquine treatment. bit.ly/2W5meov
The study did not formally assess clinical endpoints, and it is unclear whether there is #COVID19 clinical benefit with #hydroxychloroquine treatment. bit.ly/2W5meov
From Díez et al. in bioRxviv:
Several IV #immunoglobulin preps had antibodies that cross-reacted with #SARSCoV2 & may be clinically useful in preventing virus from entering cells. More work needed, particularly to assess the possibility of false positives bit.ly/2YFqPiX
Several IV #immunoglobulin preps had antibodies that cross-reacted with #SARSCoV2 & may be clinically useful in preventing virus from entering cells. More work needed, particularly to assess the possibility of false positives bit.ly/2YFqPiX
From Cao et al. in @NEJM:
Efficacy of #lopinavir #ritonavir combo: for hospitalized severe #COVID19, no clinical benefit seen 10+ days after admission compared to standard of care. Looked at time to clinical improvement, mortality & viral load. bit.ly/2KYwp8a
Efficacy of #lopinavir #ritonavir combo: for hospitalized severe #COVID19, no clinical benefit seen 10+ days after admission compared to standard of care. Looked at time to clinical improvement, mortality & viral load. bit.ly/2KYwp8a
From Cao et al. in @NEJM:
Safety of #lopinavir #ritonavir combo: among the 199 hospitalized #COVID19 patients, GI side effects more common in lopinavir-ritonavir, and serious adverse events more common in standard of care group. bit.ly/2KYwp8a
Safety of #lopinavir #ritonavir combo: among the 199 hospitalized #COVID19 patients, GI side effects more common in lopinavir-ritonavir, and serious adverse events more common in standard of care group. bit.ly/2KYwp8a
In short, no convincing evidence (yet?) to support efficacy of any of #hydroxychloroquine, #immunoglobulin or #lopinavir #ritonavir among persons hospitalized with #COVID19. Check out full expert summary statements at our website ncrc.jhsph.edu
If you're looking for information about #remdesivir, check back in later this week! We are working to evaluate and interpret recently released data, and will have summaries to share.
